Bagsværd, Denmark, 29 April 2015 - In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. 

Referring to Company Announcement no 27/2015 dated 22 April 2015, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 29 April 2015.

Further information

Media:    
Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com:
mailto:amhg@novonordisk.com
 

Investors:		    
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com:
mailto:krop@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com:
mailto:dabo@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com:
mailto:mrz@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com:
mailto:fdni@novonordisk.com

Company announcement No 30 / 2015


Company announcement No 30 / 2015:
http://hugin.info/2013/R/1916602/685391.pdf


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
HUG#1916602